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IL-15 exhibits potent antitumor efficacy in mouse mod-
els through its ability to promote proliferation and acti-
vation of NK cells and memory CD8+ T cells. Recently,
targeting approaches have been developed to direct
these activities against tumor cells and minimize poten-
tial toxicities related to systemic immune activation.
IL-15 and its receptor a (IL-15Ra) are co-expressed in
antigen presenting cells allowing trans-presentation of
IL-15 to immune effector cells. We previously reported
that the high-affinity interactions between an IL-15
superagonist (IL-15N72D) and the extracellular IL-15Ra
sushi domain (IL-15RaSu) could be exploited to create
a functional scaffold for the design of multivalent disea-
se-targeted protein complexes. Extending these findings
to relevant tumor antigens, a tetravalent complex
(2B8T2M) was generated comprising the single-chain
anti-human CD20 Fv domain of Rituximab linked to the
N-termini of the IL-15N72D and IL-15RaSu-Fc fusion
proteins. As designed, this complex was found to
retained IL-15 activity to induce proliferative and effec-
tor responses of CD8+ T cells and NK cells as well as
CD20- and Fc receptor-binding activity necessary to
mediate ADCC and CDC against CD20-positive B cell
lymphoma. Surprisingly, 2B8T2M (≥1 nM) was also cap-
able of inducing significant apoptosis of B cell lym-
phoma cells, which was not observed following
incubation with Rituximab (Daudi cell death: 2B8T2M;
36.5 ± 0.5% vs. Rituximab; 8.5 ± 0.3%). Moreover, treat-
ment of tumor-bearing SCID mice with 2B8T2M
(12.5 mg/kg, day 15, 18 post-tumor injection) was more
effective than Rituximab (10 mg/kg equivalent to 12.5 mg/
kg 2B8T2M) in reducing levels of CD20-positive Daudi
lymphoma cells in the bone marrow (% BM Daudi cells at
day 22: 2B8T2M, 1.4 ± 1.3% vs. Rituximab, 28.1 ± 6.2%;
vs. PBS, 42.1 ± 8.0%; both p < 0.01). This antitumor activ-
ity was dependent on each of the three binding domains
of 2B8T2M. In addition, 5 mg/kg 2B8T2M treatment of
Daudi tumor-bearing SCID mice significantly prol-
onged survival compared to PBS control- and 10 mg/kg
Rituximab-treatment groups (median survival: 2B8T2M,
42 days vs. Rituximab, 35 days; vs. PBS, 27 days; both
p < 0.01). In cynomolgus monkeys, 2B8T2M administra-
tion (5 mg/kg, day 0, 3) also exhibited greater activity than
Rituximab (10 mg/kg) for depleting B cells in the blood
and lymph nodes (p < 0.05). 2B8T2M treatment was well
tolerated in each of these models. Together, these finding
demonstrate that tumor antigen-targeted IL-15 complexes
can stimulate and direct immune responses to more effec-
tively eliminate tumor cells than related therapeutic anti-
bodies. Thus, these molecules represent novel and
promising targeted immunotherapeutics for treating
cancer.
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